STOCK TITAN

AEON Biopharma (AEON) Stock Price, News & Analysis

AEON NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
85 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-33.3% close of July 13, 2026
1-year change
-85% closing prices, November 20, 2025 to November 20, 2026
1-month change
-46.9% closing prices, October 20, 2026 to November 20, 2026

Company Description

AEON Biopharma, Inc. (AEON) is a clinical-stage biopharmaceutical company focused on research and development in biotechnology. The company is centered on developing its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market. AEON’s shares trade on the NYSE American under the ticker symbol AEON.

According to multiple company disclosures, ABP-450 is the same botulinum toxin complex that is approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau. AEON is pursuing development of ABP-450 for therapeutic indications, positioning the product as a proposed biosimilar to BOTOX (onabotulinumtoxinA) under the U.S. biosimilar regulatory framework. The company describes itself as seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX.

AEON highlights that the U.S. therapeutic neurotoxin market exceeds a multi-billion dollar annual size, which it views as a significant opportunity for biosimilar entry. Its strategy centers on using the Public Health Service Act’s 351(k) biosimilar pathway, with BOTOX as the proposed reference product for therapeutic indications. Under this pathway, developers must demonstrate that a proposed biosimilar is highly similar to the reference biologic, with no clinically meaningful differences in safety, purity, or potency. AEON emphasizes that analytical similarity is the scientific foundation of this process and a critical, data-intensive phase of development.

ABP-450 and manufacturing foundation

AEON’s lead asset, ABP-450 injection, is a botulinum toxin type A complex. Company materials state that ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice (cGMP). The manufacturing facility has been approved by the U.S. Food and Drug Administration (FDA), Health Canada, and the European Medicines Agency. AEON points to this globally scaled manufacturing platform and regulatory history as an important underpinning for its biosimilar development program.

The product is described as being approved as a biosimilar in India, Mexico, and the Philippines (and in some disclosures, specifically in Mexico and India). AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. These rights define the geographic scope within which AEON can develop and potentially commercialize ABP-450 for therapeutic uses.

Therapeutic focus and neurosciences orientation

Across its public statements, AEON describes itself as focusing on debilitating medical conditions and, in several instances, specifies an initial focus on the neurosciences market. While individual disease indications are not detailed in the provided materials, the company consistently frames ABP-450 as a therapeutic neurotoxin candidate intended for multiple therapeutic indications, using BOTOX’s therapeutic label as the reference framework under the biosimilar pathway.

AEON characterizes its development plan as aligned with the FDA on initial key requirements to proceed under the 351(k) biosimilar regulatory pathway. The company reports conducting primary analytical studies and preparing for a Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA. This meeting is intended to review the analytical development plan and initial data supporting biosimilarity and to determine the next steps in development.

Analytical biosimilarity work

In its third quarter 2025 update, AEON reported positive biosimilarity data for ABP-450 as a proposed biosimilar to BOTOX. The company states that analytical results confirmed identical amino-acid sequencing of all visible portions and highly similar functional characteristics compared with BOTOX. It further notes that LC-MS analysis demonstrated that the primary structure of ABP-450 exhibited a 100% amino-acid sequence match to BOTOX, with high sequence coverage across all five proteins comprising the 900 kDa botulinum toxin type A complex. These data were submitted to the FDA ahead of the planned Type 2a meeting.

AEON repeatedly underscores that once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on whether any residual uncertainty requires limited clinical evaluation. This reflects the company’s emphasis on analytical similarity as the cornerstone of its biosimilar strategy for ABP-450.

Corporate structure, listing, and financing activities

AEON Biopharma, Inc. is incorporated in Delaware and its Class A common stock is listed on the NYSE American under the symbol AEON, as confirmed in multiple Form 8-K filings. The company has reported that the NYSE American accepted its plan to regain compliance with continued listing standards relating to minimum market capitalization and stockholders’ equity, granting a plan period through a specified future date, subject to ongoing review.

To support its development program and capital structure, AEON has entered into several financing and restructuring transactions. These include:

  • A private placement (PIPE) securities purchase agreement with institutional investors, involving the issuance of Class A common stock, pre-funded warrants, warrants, and true-up warrants.
  • A term sheet and subsequent Exchange Agreement with Daewoong Pharmaceutical to exchange outstanding senior secured convertible notes for new equity, a new senior secured convertible note due 2030, and warrants to purchase shares of common stock.
  • Company estimates that, subject to stockholder approval and closing conditions, the exchange would eliminate a substantial portion of its outstanding debt and modify its capital structure.

These transactions are described in detail in AEON’s Form 8-K filings and its definitive proxy statement for a special meeting of stockholders, which outlines proposals related to the PIPE financing, the Daewoong note exchange, and amendments to the company’s incentive award plan.

Regulatory and governance context

AEON’s filings and press releases emphasize the importance of regulatory interactions with the FDA under the 351(k) biosimilar pathway. The company has disclosed plans and scheduling updates for a BPD Type 2a meeting, which is intended to review its analytical development plan and initial biosimilarity data. AEON also notes that extensive preclinical toxicology and other data have been generated by its licensing partner, although specific datasets are not detailed in the provided materials.

On the governance side, AEON has reported equity inducement grants to newly hired non-executive employees and to its President and Chief Executive Officer under inducement incentive plans. These grants, typically in the form of restricted stock units (RSUs) and stock options, vest over four years with 25% vesting on each annual anniversary of the vesting commencement date. The company states that these awards are intended as material inducements to employment in accordance with Section 711 of the NYSE American Company Guide.

Management and expertise

AEON describes itself as having built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. Public disclosures note the appointment of a new President and Chief Executive Officer, with prior leadership roles in the therapeutic toxin industry and broader life sciences sector. The company positions this experience as aligned with its focus on advancing ABP-450 along the biosimilar regulatory pathway and navigating the therapeutic neurotoxin market.

Business model orientation

Based on the information provided, AEON’s business model is centered on clinical-stage development of a single lead asset, ABP-450, for therapeutic indications. The company’s strategy relies on:

  • Leveraging an existing, globally approved botulinum toxin complex (Jeuveau/ABP-450) as the basis for a therapeutic biosimilar program.
  • Pursuing regulatory approval under the 351(k) biosimilar pathway using BOTOX as the reference product.
  • Utilizing exclusive territorial rights for therapeutic indications in key markets, including the U.S., Canada, the EU, and the UK.
  • Securing financing and restructuring existing obligations to fund analytical and regulatory work.

AEON’s disclosures do not detail commercial-stage revenues; instead, they focus on research and development activities, regulatory planning, capital resources, and changes in fair value of financial instruments such as convertible notes, warrants, and contingent consideration.

Risk and regulatory disclosures

Company press releases and SEC filings contain extensive forward-looking statements language, noting that outcomes of analytical studies, regulatory meetings, financing transactions, listing compliance, and other factors may differ from expectations. AEON directs readers to the “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” sections of its filings with the Securities and Exchange Commission for a more detailed discussion of risks, including capital requirements, regulatory uncertainties, and stock exchange listing standards.

Stock Performance

$0.1240
+0.81%
+0.0010
After hoursChange vs the $0.1230 closeLast updated: at
-85%
Performance 1 year
$10.4M
84.1M
Shares outstanding As of November 13, 2026.

AEON Biopharma (AEON) closed at $0.1230 on November 20, 2026. Over the past 12 months, the price has lost 85.0%.

See what a $1,000 investment in AEON would be worth today

Average down calculator for AEON

AEON Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

SEC Filings

AEON Biopharma has filed 10 recent SEC filings, including 4 Form 4, 2 Form SCHEDULE 13G, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AEON SEC filings →

Insider Radar

Net Buyers
90-Day Summary
441,885
Shares Bought
0
Shares Sold
3
Transactions
Most Recent Transaction
Wilson Alexander Blair (CLO, CSO and Corp Secretary) bought 135,706 shares @ $0.1288 on November 20, 2026

Insider buying activity at AEON Biopharma over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

AEON Biopharma reported operating income of -$12.8M in FY2025, and net income was -$39.2M. Diluted earnings per share stood at -$3.95. The company generated -$17.3M in operating cash flow. The current ratio was 0.49, measuring current assets divided by current liabilities.

-$39.2M
Net Income (FY2025)
-$17.3M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
11
December 11, 2026 Corporate

RSU vesting (25%)

First annual tranche: 25% of 392,158 RSUs vest per 2025 Inducement Plan
Q1
2027
Q1 2027 Clinical

ABP-450 human study

Two-stage human study of ABP-450 to start Q1 2027; FDA agreed in principle. Sponsored by AEON Biopharma; application submitted.
Q1
2027
Q1 2027 Clinical

ABP-450 study start

Planned ABP-450 vs BOTOX comparative study using CMAP. IND filed; initiation expected Q1 2027, subject to FDA requirements.
H1
2027
H1 2027 Regulatory

Multi-lot comparability study

Initiation of multi-lot comparability study for ABP-450 to support a planned 351(k) BLA; targeted start in H1 2027 (Jan–Jun).
Q1
2027
Q1 2027 Clinical

Study initiation

AEON expects to initiate the comparative dose-finding study for ABP-450 in Q1 2027 following IND clearance.
Q1
2027
Q1 2027 Regulatory

Return to FDA meeting

AEON plans to return to the FDA in 2027 with integrated evidence and migraine-study analyses for ABP-450.
MAR
09
March 9, 2027 Corporate

RSU 25% vesting

25% of 754,717 RSUs vest per inducement award (annual tranche).
MAR
09
March 9, 2027 Corporate

RSU vesting installment

25% of 150,000 restricted stock units vest on this date under the 2025 Inducement Plan; potential minor dilution.
DEC
11
December 11, 2027 Corporate

RSU vesting (25%)

Second annual tranche: 25% of 392,158 RSUs vest per 2025 Inducement Plan
MAR
09
March 9, 2028 Corporate

RSU 25% vesting

25% of 754,717 RSUs vest per inducement award (annual tranche).
MAR
09
March 9, 2028 Corporate

RSU vesting installment

25% of 150,000 restricted stock units vest on this date under the 2025 Inducement Plan; potential minor dilution.
DEC
11
December 11, 2028 Corporate

RSU vesting (25%)

Third annual tranche: 25% of 392,158 RSUs vest per 2025 Inducement Plan
MAR
09
March 9, 2029 Corporate

RSU 25% vesting

25% of 754,717 RSUs vest per inducement award (annual tranche).
MAR
09
March 9, 2029 Corporate

RSU vesting installment

25% of 150,000 restricted stock units vest on this date under the 2025 Inducement Plan; potential minor dilution.
DEC
11
December 11, 2029 Corporate

RSU vesting (25%)

Final annual tranche: remaining 25% of 392,158 RSUs vest per plan

AEON Biopharma has 15 upcoming scheduled events. The next event, "RSU vesting (25%)", is scheduled for December 11, 2026 (in 20 days). Investors can track these dates to stay informed about potential catalysts that may affect the AEON stock price.

Short Interest History

Last 12 Months

Short interest in AEON Biopharma (AEON) currently stands at 2.7 million shares, down 18.1% from the previous reporting period, representing 5.4% of the float. Since November 2025, short interest has increased by 4642.7%.

Days to Cover History

Last 12 Months

Days to cover for AEON Biopharma (AEON) currently stands at 6.4 days, up 321.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 540%. Across the settlements charted above, it has ranged from 1.0 to 6.4 days.

AEON Company Profile & Sector Positioning

AEON Biopharma (AEON) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing AEON often look at related companies in the same sector, including Vyome Holdings, Inc. (HIND), Palatin Technologies, Inc. (PTN), Psyence Biomedical Ltd. (PBM), Cellectar Biosciences INC NEW (CLRB), and Anebulo Pharmac Inc (ANEB). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AEON's relative position within its industry.

Frequently Asked Questions

The current stock price of AEON Biopharma (AEON) is $0.1240 in after-hours trading as of November 20, 2026.

The market cap of AEON Biopharma (AEON) is approximately $10.4M. Learn more about what market capitalization means .

The FY2025 net income of AEON Biopharma (AEON) is -$39.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of AEON Biopharma (AEON) is -$3.95 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of AEON Biopharma (AEON) is -$17.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of AEON Biopharma (AEON), current assets divided by current liabilities, was 0.49 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of AEON Biopharma (AEON) is -$12.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, for debilitating medical conditions, with an initial focus on the neurosciences market.

ABP-450 is AEON’s lead asset, a botulinum toxin type A complex developed as an injection for therapeutic use. AEON is pursuing development of ABP-450 as a proposed biosimilar to BOTOX (onabotulinumtoxinA) under the FDA’s 351(k) biosimilar pathway.

According to AEON’s disclosures, ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that operates under current Good Manufacturing Practice (cGMP) and has been approved by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency.

AEON reports that it has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.

AEON Biopharma, Inc.’s Class A common stock is listed on the NYSE American under the ticker symbol AEON, as indicated in its Form 8-K filings.

The 351(k) biosimilar pathway is the U.S. FDA’s regulatory route for biosimilars under the Public Health Service Act. It requires developers to demonstrate that a proposed product is highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. AEON is using this pathway for ABP-450 with BOTOX as the reference product.

AEON has reported analytical results indicating that ABP-450 has identical amino-acid sequencing of all visible portions and highly similar functional characteristics compared with BOTOX. LC-MS analysis showed a 100% amino-acid sequence match to BOTOX with high sequence coverage across all five proteins of the 900 kDa botulinum toxin type A complex.

AEON has entered into a private placement (PIPE) with institutional investors involving common stock and various warrants, and it has executed an Exchange Agreement with Daewoong Pharmaceutical to convert existing senior secured convertible notes into new equity, a new senior secured convertible note due 2030, and warrants, subject to stockholder approval and customary closing conditions.

AEON states that it has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization, and has highlighted leadership appointments with prior roles in the therapeutic toxin and broader life sciences industries.